drugset / Trial / NCT05816642

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

NCT05816642

Unknown 500 enrolled RenJi Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChangzhi Medical College · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabFudan University · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabQuanzhou First Hospital · collabRuijin Hospital · collabSecond Affiliated Hospital of Nantong University · collabSecond Affiliated Hospital of Xi'an Jiaotong University · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabShanghai Jiao Tong University Affiliated Sixth People's Hospital · collabShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · collabShanxi Province Cancer Hospital · collabSir Run Run Shaw Hospital · collabTang-Du Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First Affiliated Hospital of Air Force Medicial University · collabThe First Affiliated Hospital of Shanxi Medical University · collabThe First Affiliated Hospital of University of Science and Technology of China · collabThe First Affiliated Hospital of Zhengzhou University · collabThe First Affiliated Hospital with Nanjing Medical University · collabThe General Hospital of Eastern Theater Command · collabThe Second Hospital of Anhui Medical University · collabThird Affiliated Hospital, Sun Yat-Sen University · collabTongji Hospital · collabWest China Hospital · collabXiangya Hospital of Central South University · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collabZhejiang University · collab
Non-randomizedParallel-groupOpen-labelScreening

Summary

Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.

Timeline

Start
2022-08-01
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule
Comparator Pazopanib Small molecule
Comparator Sunitinib Small molecule

Indications